vTv Therapeutics (VTVT) announced positive top-line results from a Phase 2b study evaluating its liver-selective glucokinase activator TTP399 for the treatment of type 2 diabetes. The trial achieved its primary endpoint of a statistically valid reduction from baseline in HbA1c at day 168. Patients received a daily oral dose of 800 mg of TTP399. The reduction in HbA1c was dose-dependent and sustained throughout the study period.